Neurobiology of depression and novel antidepressant drug targets

Current Pharmaceutical Design

Volumn 18, Issue 32, 2012, Pages 5791-5801

  Kern, Nikola ^a   Sheldrick, Abigail J ^b,c   Schmidt, Frank M ^d   Minkwitz, Juliane ^d  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antidepressants; Depression; Epigenetics; Genetics; Neurobiology; Neurochemistry; Neuroendocrinology; Neuroimmunology; Novel drug targets

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENTARY DNA; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE; DOPAMINE 4 RECEPTOR; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; IMIPRAMINE; MELATONIN; MIFEPRISTONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEU DIFFERENTIATION FACTOR; NORADRENALIN; RECOMBINANT SOMATOMEDIN C; RESERPINE; ROBATUMUMAB; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; TIANEPTINE;

CIRCADIAN RHYTHM; DEPRESSION; DNA METHYLATION; DNA SEQUENCE; DRUG RECEPTOR BINDING; ELECTROCONVULSIVE THERAPY; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC LINKAGE; GLIA; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROANATOMY; NEUROBIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEROTONIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG TARGETING; MOLECULAR GENETICS; NEUROCHEMISTRY; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CIRCADIAN RHYTHM; DEPRESSION; DRUG DESIGN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEUROGENESIS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84867725234     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803523581     Document Type: Review

References (156)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age of onset distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
2. World Health Organization Web site. Depression. http://www.who.int/mental_health/management/depression/definition/en/. Accessed April 2012.
3. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med 1999; 61: 6-17.
4. Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121: 174-9.
5. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment -resistant depression. CNS Drugs 2010; 24: 131-61.
6. Maier W, Schwab S, Rietschel M. Epidemiologie affektiver Störungen. In: Helmchen H, Henn F, Lauter H, Sartorius N, Eds. Psychiatrie der Gegenwart 5, Schizophrene und affektive Störungen. 4th ed. Berlin: Springer 2000; pp. 373-407.
7. Angst J, Cui L, Swendsen J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010; 167: 1194-201.
8. McMahon FJ, Akula N, Schulze TG, et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet 2010; 42: 128-31.
9. Shyn SI, Shi J, Kraft JB, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry 2011; 16: 202-15.
10. Sullivan PF, de Geus EJ, Willemsen G, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 2009; 14: 359-75.
11. Shi J, Potash JB, Knowles JA, et al. Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 2011; 16: 193-201.
12. Lewis CM, Ng MY, Butler AW, et al. Genome-wide association study of major recurrent depression in the U.K. population. Am J Psychiatry 2010; 167: 949-57.
13. Ferreira MAR, O'Donovan MC, Meng YA, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-8.
14. López-León S, Janssens AC, González-Zuloeta Ladd AM, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 2008; 13: 772-85.
15. Serretti A, Mandelli L. The genetics of bipolar disorder: Genome "hot regions," genes, new potential candidates and future directions. Mol Psychiatry 2008; 13: 742-71.
16. Pereira AC, McQuillin A, Puri V, et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156: 177-87.
17. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 2009; 23(Suppl 2): S15-226.
18. Kendler KS, Kessler RC, Walters EE, et al. Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiatry 1995; 152: 833-42.
19. Silberg J, Rutter M, Neale M, et al. Genetic moderation of environmental risk for depression and anxiety in adolescent girls. Br J Psychiatry 2001; 179: 116-21
20. Silberg J, Pickles A, Rutter M, et al. The influence of genetic factors and life stress on depression among adolescent girls. Arch Gen Psychiatry 1999; 56: 225-32.
21. Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299: 1291-305.
22. Lee RS, Tamashiro KL, Yang X, et al. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 2010; 151: 4332-43.
23. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008; 63: 1103-10.
24. Willour VL, Chen H, Toolan J, et al. Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2009; 14: 261-8.
25. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9.
26. Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005; 62: 146-52.
27. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-64.
28. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-8.
29. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-57.
30. Benedetti F, Colombo C, Pirovano A, et al. The catechol-Omethyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology 2009; 203: 155-60.
31. Tsai MH, Lin KM, Hsiao MC, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11: 537-46.
32. Mehta D, Menke A, Binder EB. Gene Expression studies in major depression. Curr Psychiatry Rep 2010; 12: 135-44.
33. Choi KH, Higgs BW, Wendland JR, Song J, McMahon FJ, Webster MJ. Gene Expression and Genetic Variation Data Implicate PCLO in Bipolar Disorder. Biol Psychiatry 2011; 69: 353-9.
34. McMahon FJ, Akula N, Schulze TG, et al. Bipolar Disorder Genome Study (BiGS) Consortium. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet 2010; 42: 128-31.
35. Schroeder M, Krebs MO, Bleich S, Frieling H. Epigenetics and depression: current challenges and new therapeutic options. Curr Opin Psychiatry 2010; 23: 588-92.
36. Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug targets 2005; 4: 41-50.
37. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetiv programming by maternal behavior. Nat Neurosci 2004; 7: 847-54.
38. Covington HE, Maze I, LaPlant QC, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009; 29: 11451-60
39. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem 2001; 276: 36734-41.
40. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2010; 48: 813-29.
41. Geuze E, Vermetten E, Bremner JD. MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol Psychiatry 2005; 10: 160-84.
42. Fuchs E, Flügge G. Depressionen: Eine Störung der Neuroplastizität? Psychoneuro 2005; 31: 197-203.
43. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-8.
44. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19: 269-301.
45. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999; 22: 105-22.
46. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 1999; 46: 1595-602.
47. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009; 33: 699-771.
48. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22.
49. Schildkraut JJ. Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting response to treatment. Am J Psychiatry 1973; 130: 695-9.
50. Arango V, Underwood MD, Mann JJ. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry 1996; 39: 112-20.
51. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997; 17: 8451-8.
52. West CH, Ritchie JC, Boss-Williams KA, Weiss JM. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol 2009; 12: 627-41.
53. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967; 113: 1237-64.
54. Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig 1998; 15: 45-55.
55. Lowther S, de Paermetier F, Crompton MR, Katona CLE, Horton RW. Brain 5-HT2 receptor in suicide victims: violence of death, depression and effects of antidepressant treatment. Brain Res 1994; 642: 281-9.
56. Lowther S, Katona CLE, Crompton MR, Horton RW. 5-HT1D and 5-HT1E/1F binding sites in depressed suicides: increased 5-HT1D binding in globus pallidus but not cortex. Mol Psychiatry 1997; 2: 314-21.
57. Arborelius L. 5-HTA receptor antagonists as putative adjuvants to antidepressants: preclinical and clinical evidence. I Drugs 1999; 2: 121-8.
58. Chen L, Zhou W, Chen P, Gaisina I, Yang S, Li X. Glycogen synthase-3beta is a functional modulator of serotonin 1B receptors. Mol Pharmacol 2011; 79: 974-98.
59. Tamburella A, Micale V, Navarria A, Drago F. Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1205-10.
60. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990; 5: 14-20.
61. Nickel T, Sonntag A, Schill J, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 2003; 23: 155-68.
62. Brown AS, Gershon S. Dopamine and depression. J Neural Transm 1993; 91: 75-109.
63. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 2001; 21: RC157: 1-4.
64. Keck ME, Erhard A, Müller MB, et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and neostriatal system. Neuropharmacology 2002; 43: 101-9.
65. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985; 19: 57-64.
66. Popik P, Krawczyk M, Golembiowska K, et al. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102, 677. Cell Mol Neurobiol 2006; 26: 857-73.
67. Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216, 303, a "triple" reuptake inhibitor. CNS Drug Rev 2006; 12: 123-34
68. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65.
69. Piazza PV, Barrot M, Rougé-Pont F, et al. Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proc Natl Acad Sci USA 1996; 93: 15445-50.
70. Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52: 386-92.
71. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010; 12: CD008121.
72. Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005; 25: 3270-9
73. Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression? Neuroscience 2000; 100: 681-4.
74. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998; 97: 302-8.
75. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822-5.
76. Zarate Jr CA, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-2.
77. Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurptransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010; 35: 834-46.
78. Berk M, Copolov DL, Dean O, et al. N-acetylcysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-75.
79. Machado-Vieira R, Manji HK, Zarate CA. Role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009; 15: 525-39.
80. Maeng S, Zarate Jr CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-52.
81. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009; 15: 525-39.
82. Zarate CA, Quroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36: 35-83.
83. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007; 115: 116-47.
84. Kinney GG, O'Brien JA, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005; 313: 199-206.
85. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-Daspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71: 1605-11.
86. Garcia LS, Comim CM, Valvassori SS, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increased BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 140-4.
87. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebocontrolled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-5.
88. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71: 1273-88.
89. Furey ML, Drevets WC. Antidepressant efficacy of the muscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006; 63: 1121-9.
90. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebocontrolled clinical trial. Biol Psychiatry 2010; 67: 432-8.
91. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64.
92. Kalman D, Smith SS. Does nicotine do what we think it does? A meta-analytic review of the subjective effects of nicotine in nasal spray and intravenous studies with smokers and nonsmokers. Nicotine Tob Res 2005; 7: 317-33.
93. Andreasen JT, Redrobe JP. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol 2009; 20: 286-95.
94. Voss B, Thienel R, Reske M, Habel U, Kircher T. Cognitive performance and cholinergic transmission: influence of muscarinic and nicotinic receptor blockade. Euro Arch Psychiatry Clin Neurosci 2010; 260 (Suppl 2): 106-10.
95. Keck ME. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids 2006; 31: 241-50.
96. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-13.
97. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-59.
98. Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-15.
99. Hill MN, Miller GE, Ho WS, et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008; 41: 48-53.
100. Ising M, Holsboer F. Genetics of stress response and stress-related disorders. Dialogues Clin Neurosci 2006; 8: 433-44.
101. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
102. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 1999; 46: 1480-508.
103. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 2001; 35: 83-94.
104. Ising M, Horstmann S, Kloiber S, et al. Combined examethasone/ corticotropin releasing hormone test predicts treatment response in major depression -αa potential biomarker? Biol Psychiatry 2007; 62: 47-54.
105. Schmider J, Lammers C-H, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995; 38: 797-802.
106. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychsom Med 2005; 67 (Suppl 1): S26-8.
107. De Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nature Rev Neurosci 2005; 6: 463-75.
108. Keck ME, Ohl F, Holsboer F, Muller MB. Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev 2005; 29: 867-89.
109. Zobel AW, Nickel T, Künzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatry Res 2000; 34: 171-81.
110. Yakabi K, Noguchi M, Ohno S, Ro S, Onouchi T, Ochiai M, Takabayashi H, Takayama K, Harada Y, Sadakane C, Hattori T. Urocortin 1 reduces food intake and ghrelin secretion via CRF(2) receptors. Am J Physiol Endocrinol Metab 2011; 301(1): E72-82. Epub 2011 May 3.
111. JEmeto TI, Moxon JV, Rush C, Woodward L, Golledge J. Relevance of urocortins to cardiovascular disease. Mol Cell Cardiol 2011; 51(3): 299-307. Epub 2011 Jun 12.
112. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 2011 Sep 21; 306(11): 1241-9.
113. Keck ME, Welt T, Muller MB, et al. Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic ParoxetineTreatment in a Psychopathological Rat Model. Neuropsychopharmacology 2003; 28: 235-43.
114. De Winter RF, van Hemert AM, DeRijk RH, et al. Anxiousretarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003; 28: 140-7.
115. Pariante CM. The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol 2006; 20 (Suppl 4): S79-84.
116. Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 2008; 23: CD005168.
117. Flores BH, Kenna H, Keller J, Brent Solvason H, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropharmacology 2006; 31: 628-36.
118. Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen - Kritische Übersicht und Perspektiven. Nervenarzt 1993; 64: 1-10.
119. Hage MP, Azar ST. The Link between Thyroid Function and Depression. J Thyroid Res 2012; 2012: 590648.
120. Himmerich H, Veselinovic T, Habel U. Die Stimmung im Spiegel der weiblichen Lebensphasen. Info Neurologie & Psychiatrie 2009; 3: 42-8.
121. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009; 15: 289-305.
122. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993; 269: 2760-4.
123. Malone DA Jr, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med 1995; 5: 25-31.
124. McNutt MD, Liu S, Manatunga A, et al. Neurobehavioral Effects of Interferon-ć in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine. Neuropsychopharmacology 2012; 37: 1444-54.
125. Himmerich H, Berthold-Losleben M, Pollmächer T. Die Bedeutung des TNF-α-Systems für Erkrankungen des Gehirns. Fortschr Neurol Psychiatr 2009; 77: 334-45.
126. Himmerich H, Milenović S, Fulda S, et al. Regulatory T cells increased while IL-1ć decreased during antidepressant therapy. J Psychiatr Res 2010; 44: 1052-7
127. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009; 30: 497-521.
128. Li X, Frye MA, Shelton RC. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 2011; Epub: doi: 10.1038/npp.2011.198.
129. Machado-Vieira R, Salvadore G, DiazGranados N, et al. New therapeutic drug targets for mood disorders. ScientificWorldJournal 2010; 10: 713-726.
130. Buysse DJ, Hall M, Tu XM, et al. Latent structure of EEG sleep variables in depressed and control subjects: descriptions and clinical correlates. Psychiatry Res 1998; 79: 105-22.
131. Buysse DJ, Hall M, Tu XM, et al. Latent structure of EEG sleep variables in depressed and control subjects: descriptions and clinical correlates. Psychiatry Res 1998; 79: 105-22.
132. Souêtre E, Salvati E, Rix H, et al. Effect of recovery on the cortisol circadian rhythm of depressed patients. Biol Psychiatry 1988; 24: 336-40.
133. De Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-42.
134. Bersani G, Garavini A. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 185-91.
135. Van Oekelen D, Luyten WH, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003; 72: 2429-49.
136. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007; 9: 628-35.
137. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Euro Neuropsychopharmacol 2006; 16: 93-100.
138. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283-91.
139. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24: 479-99.
140. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002; 3: 306-10.
141. Barbosa IG, Huguet RB, Neves FS, et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J Biol Psychiatry 2011; 12: 228-32.
142. Brunoni AR, Lopes M, Fregni F. A systematic review and metaanalysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-80.
143. Alboni S, Tascedda F, Corsini D, et al. Stress induces altered CRE/CREB pathway activity and BDNF expression in the hippocampus of glucocorticoid receptor-impaired mice. Neuropharmacology 2011; 60: 1337-46
144. Duman RS, Henninger GR, Nestler EJ. A molecular and cellular therapy of depression. Arch gen Psychiatry 1997; 54: 1026-32.
145. Yasui-Furukori N, Tsuchimine S, Nagakami T, et al. Association between plasma paroxetine concentration and changes in plasma brain derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol 2011; Epub: doi: 10.1002/hup.1192.
146. Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-6.
147. Jiang B, Xiong Z, Yang J, et al. Antidepressant-like effects of Ginsenoside Rg1 produced by activation of BDNF signaling pathway and neurogenesis in the hippocampus. Br J Pharmacol 2012 [Epub ahead of print]
148. Réus GZ, Stringari RB, Ribeiro KF, et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 2011; 221: 166-71.
149. Anlar B, Sullivan KA, Feldman EL. Insulin-like growth factor-I and central nervous system development. Horm Metab Res. 1999; 31: 120-5.
150. Schilling C, Blum WF, Heuser I, et al. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J Clin Psychopharmacol 2011; 31: 390-2.
151. Deuschle M, Blum WF, Strasburger CJ, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997; 22: 493-503.
152. Weber-Hamann B, Blum WF, Kratzsch J, et al. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009; 42: 23-8.
153. Duman CH, Schlesinger L, Terwilliger R, et al. Peripheral insulinlike growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009; 198: 366-71.
154. Mitschelen M, Yan H, Farley JA, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience 2011; 185: 50-60.
155. Evans SJ, Choudary PV, Neal CR, et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004; 101: 15506-11.
156. Minkwitz J, Himmerich H. Neurobiology of depression: Findings, controversies and perspectives (Editorial). Neuropsychiatry 2011; 1: 199-202.